LIFECORE BIOMEDICAL INC (LFCR)
Health Care · Regenerative medicine and tissue engineering · NASDAQ
LifeCore Biomedical develops and manufactures regenerative medicine products for tissue repair and reconstruction.
What LIFECORE BIOMEDICAL INC does
LifeCore Biomedical is a regenerative medicine company that develops, manufactures, and commercializes biomedical products used in tissue repair, reconstruction, and regeneration. The company generates revenue from both direct product sales and related-party transactions. LifeCore operates a single reportable business segment focused on bringing regenerative medicine solutions to market. The company is currently unprofitable but experiencing revenue growth, with 27.59% YoY growth as of the latest reporting period.
Themes: ["Regenerative medicine"]
Fundamentals
- Price$4.75 as of 2026-07-09 close
- Market cap$170M as of 2026-07-10
- 1-year return-41.7% as of 2026-07-09 close
- Net margin-26.5% as of 2026-07-10
- Gross margin+30.0% as of 2026-07-10
- ROE-126.8% as of 2026-07-10
- Debt / equity7.16 as of 2026-07-10
- Revenue growth (YoY)+27.6% as of 2026-07-10
- Revenue CAGR (3y)+5.3% SEC XBRL
- Beta1.11 as of 2026-07-10
Key risks (from latest filing)
["Company is unprofitable with significant accumulated deficit of $238.2 million, raising concerns about path to profitability and cash burn sustainability"]
Competitors & peers
- Arthrex
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.